Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Incyte's Pre-Tax Income for the
three
months ended in Dec. 2023 was $271 Mil. Incyte's Revenue for the
three
months ended in Dec. 2023 was $1,013 Mil. Therefore, Incyte's pretax margin for the quarter that ended in Dec. 2023 was 26.74%.
The historical rank and industry rank for Incyte's Pretax Margin % or its related term are showing as below:
INCY'
s Pretax Margin % Range Over the Past 10 Years
Min: -20.33 Med: 7.92 Max: 22.57
Current: 22.57
INCY's Pretax Margin % is ranked better than 88.89% of 1026
companies
in the Biotechnology industry
Industry Median: -178.425
vs INCY: 22.57
Incyte Pretax Margin % Historical Data
The historical data trend for Incyte's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Pretax Margin % Distribution
For the Biotechnology industry and Healthcare sector, Incyte's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Incyte's Pretax Margin % falls into.
Incyte Pretax Margin % Calculation
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Incyte's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Incyte Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Incyte's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 